DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Price Performance

DBV Technologies stock opened at $0.76 on Wednesday. The firm’s 50 day simple moving average is $0.84 and its 200-day simple moving average is $0.96. The company has a market cap of $145.74 million, a P/E ratio of -1.94 and a beta of 0.76. DBV Technologies has a fifty-two week low of $0.65 and a fifty-two week high of $2.37.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.10. The business had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period last year, the firm posted ($0.23) earnings per share. On average, analysts expect that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC purchased a new position in DBV Technologies during the third quarter valued at approximately $26,000. BNP Paribas Arbitrage SA purchased a new position in DBV Technologies during the second quarter valued at approximately $49,000. Citadel Advisors LLC purchased a new position in DBV Technologies during the second quarter valued at approximately $55,000. OLD Mission Capital LLC grew its position in DBV Technologies by 243.7% during the first quarter. OLD Mission Capital LLC now owns 30,597 shares of the company’s stock valued at $52,000 after purchasing an additional 21,694 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in DBV Technologies during the fourth quarter valued at approximately $54,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.